Andreas Klosterman, Ph.D. (CSO) will give an update on selectION’s best-in-class ion channel antagonists and discuss the principles of the company’s systematical peptide design to obtain the most selective and specific ion channel blockers.
- selectION, Inc. Announces $4.1M Series A Investment
- selectION, Inc. Strengthens Scientific Advisory Team with the Appointment of Fred Ramsdell, Ph.D. & Mark Benedyk, Ph.D. as Strategic Advisors and Members of the Scientific Advisory Board
- selectION, Inc. Strengthens its Leadership and Scientific Team with the Appointment of Cam Gallagher to its Board of Directors & Dr. Christopher Larson, Ph.D. as Strategic Advisor and Member of the Scientific Advisory Board